



Supplementary Figure 1: Waterfall plots showing the methylation change in significant genes between normal and tumor samples involved in neurogenesis and epidermis development (GO terms). Positive values indicate hypermethylation in cancer, while negative values indicate hypomethylation in cancer.

A. Neurogenesis




B. Epidermis Development


Epidermis Development (GO)




Supplementary Figure 2: Change in average percent methylation of HOX gene family, PAX gene family, and WT1 involved in Transcription Factor Activity




Supplementary Figure 3: Unsupervised clustering of probes involved in Sequence-specific Transcription Factor Activity




Supplementary Figure 4: The status of PRC2 targets and CpG islands for those probes involved in the specified GO terms




Supplementary Figure 5: The proportion of differentially methylated genes among the PRC2 targets and non-PRC2 targets (those probes with the p-value<0.05 and the minimum difference between the average methylation percentage of tumor vs. normal greater than 5% are graphed)



Supplementary Figure 6: Clustering of metabolite, drug target, and transcription factor concepts. Hypomethylated concepts are shown in red and hypermethylated concepts are shown in green. A. Metabolite concepts. B. Drug concepts. C. Transcription Factor concepts



Supplementary Figure 7: Change in average percent methylation of the probes for TP73, CDKN1A, 1B, 1C, 2A and 2B, 2C, 2D, and APC.



Supplementary Figure 9: Bar graphs showing the methylation change in genes involved in circadian rhythm process in breast cancer. In tumor samples, the increase in the level of methylation in *DRD1*, *PTGDS*, *CASP1*, and *PGLYRP1* genes are observed.

